Ben Askew

Surf Bio is a preclinical biopharmaceutical company leveraging a novel biotechnology platform to develop enhanced therapeutic solutions for diabetes, oncology, infectious diseases, gene therapy, and other therapeutic areas. Surf Bio was launched by the founders of Bigfoot Biomedical and Mode AGC to commercialize a breakthrough drug stabilization technology developed in the Appel Lab. Commercially, the technology is designed to enable reduction of refrigeration requirements, transition from IV to subcutaneous therapy, and novel pharmaceutical formulations across a range of therapeutic areas. For more information about Surf Bio, visit www.surf.bio.

Avenge Bio was founded by an experienced team of proven biotech executives to develop transformative therapeutics which can potentially eradicate intractable solid tumors. Avenge Bio is developing our proprietary, allogeneic LOCOcyteTM platform for precision delivery of cytokines and other highly potent immunomodulatory molecules for a controlled period of time. Through this approach we are able to generate robust, local and systemic anti-tumor immune responses, without the toxicities associated with traditional immunotherapies. The LOCOcyteTM platform was developed from extensive research and experience of Dr. Omid Veiseh at Rice University and supported by Longitude Capital, CAM Capital, Perceptive Xontogeny, Rock Springs, Pappas Capital, and other leading healthcare investors. Together we are using the strength and efficiency of our platform to create a broad pipeline of therapeutics that target a wide range of difficult to treat solid tumors.

Sermonix Pharmaceuticals, founded by David Portman, MD—a leading clinical researcher and expert in women’s health—focuses on developing targeted therapeutics to treat ESR1-mutated metastatic breast and gynecological cancers. Our ELAINE Studies are evaluating an investigational oral drug, lasofoxifene, a novel targeted endocrine agent, in women and men with locally advanced or metastatic estrogen receptor-positive/human epidermal growth factor 2-negative (ER+/HER2-) breast cancer harboring an ESR1 mutation(s).

A-Alpha Bio is a biotechnology company using synthetic biology and machine learning to measure, discover, predict, and engineer protein-protein interactions. We pursue our mission of improving human health through an internal therapeutics pipeline and by partnering with industry-leading pharmaceutical and technology companies. Current approaches for measuring protein-protein interactions are insufficient for many drug development applications due to low accuracy or throughput. We are a team of synthetic biologists, structural biologists, and next-generation sequencing experts who have come together to remove this industry-wide bottleneck. Our proprietary experimental platform, AlphaSeq, generates high-resolution data to discover rare and effective antibodies, identify degradable neo-substrates for molecular glues, and generate massive protein-protein interaction datasets to map the protein binding landscape. Our AlphaBind platform then leverages these data to train predictive machine learning models to further accelerate the discovery and optimization of high-impact therapeutics. A-Alpha Bio, Inc. was founded in 2017 as a spinout from the University of Washington's Institute for Protein Design and Center for Synthetic Biology and is based in Seattle, Washington.

FRAUD ALERT: AsclepiX is aware of individuals representing job postings that are not legitimate positions. AsclepiX is NOT hiring at this time. AsclepiX Therapeutics is a clinical-stage biopharmaceutical company leveraging computational biology from Johns Hopkins to identify and develop peptides for improved treatments of retinal diseases. Our lead candidate, AXT107, inhibits pro-angiogenic vascular endothelial growth factor receptor 2 (VEGFR2) and activates the vessel stabilizing receptor tyrosine kinase (Tie2), the two validated pathways for the treatment of retinal vascular diseases.

Zucara Therapeutics, a CDRD and MaRS Innovation portfolio company, is developing the first drug therapy to prevent hypoglycemia in people with diabetes. Our first-in-class therapeutic is focused on improving glucagon counterregulation by inhibiting somatostatin which is dysregulated in Type 1 diabetes. Preventing hypoglycemia will dramatically change diabetes disease management, improving both patient health and quality of life..

Surf Bio is a preclinical biopharmaceutical company leveraging a novel biotechnology platform to develop enhanced therapeutic solutions for diabetes, oncology, infectious diseases, gene therapy, and other therapeutic areas. Surf Bio was launched by the founders of Bigfoot Biomedical and Mode AGC to commercialize a breakthrough drug stabilization technology developed in the Appel Lab. Commercially, the technology is designed to enable reduction of refrigeration requirements, transition from IV to subcutaneous therapy, and novel pharmaceutical formulations across a range of therapeutic areas. For more information about Surf Bio, visit www.surf.bio.

Avenge Bio was founded by an experienced team of proven biotech executives to develop transformative therapeutics which can potentially eradicate intractable solid tumors. Avenge Bio is developing our proprietary, allogeneic LOCOcyteTM platform for precision delivery of cytokines and other highly potent immunomodulatory molecules for a controlled period of time. Through this approach we are able to generate robust, local and systemic anti-tumor immune responses, without the toxicities associated with traditional immunotherapies. The LOCOcyteTM platform was developed from extensive research and experience of Dr. Omid Veiseh at Rice University and supported by Longitude Capital, CAM Capital, Perceptive Xontogeny, Rock Springs, Pappas Capital, and other leading healthcare investors. Together we are using the strength and efficiency of our platform to create a broad pipeline of therapeutics that target a wide range of difficult to treat solid tumors.

Sermonix Pharmaceuticals, founded by David Portman, MD—a leading clinical researcher and expert in women’s health—focuses on developing targeted therapeutics to treat ESR1-mutated metastatic breast and gynecological cancers. Our ELAINE Studies are evaluating an investigational oral drug, lasofoxifene, a novel targeted endocrine agent, in women and men with locally advanced or metastatic estrogen receptor-positive/human epidermal growth factor 2-negative (ER+/HER2-) breast cancer harboring an ESR1 mutation(s).

A-Alpha Bio is a biotechnology company using synthetic biology and machine learning to measure, discover, predict, and engineer protein-protein interactions. We pursue our mission of improving human health through an internal therapeutics pipeline and by partnering with industry-leading pharmaceutical and technology companies. Current approaches for measuring protein-protein interactions are insufficient for many drug development applications due to low accuracy or throughput. We are a team of synthetic biologists, structural biologists, and next-generation sequencing experts who have come together to remove this industry-wide bottleneck. Our proprietary experimental platform, AlphaSeq, generates high-resolution data to discover rare and effective antibodies, identify degradable neo-substrates for molecular glues, and generate massive protein-protein interaction datasets to map the protein binding landscape. Our AlphaBind platform then leverages these data to train predictive machine learning models to further accelerate the discovery and optimization of high-impact therapeutics. A-Alpha Bio, Inc. was founded in 2017 as a spinout from the University of Washington's Institute for Protein Design and Center for Synthetic Biology and is based in Seattle, Washington.

FRAUD ALERT: AsclepiX is aware of individuals representing job postings that are not legitimate positions. AsclepiX is NOT hiring at this time. AsclepiX Therapeutics is a clinical-stage biopharmaceutical company leveraging computational biology from Johns Hopkins to identify and develop peptides for improved treatments of retinal diseases. Our lead candidate, AXT107, inhibits pro-angiogenic vascular endothelial growth factor receptor 2 (VEGFR2) and activates the vessel stabilizing receptor tyrosine kinase (Tie2), the two validated pathways for the treatment of retinal vascular diseases.